(1) Research Institute and Hospital, National Cancer Center, Republic of Korea;(2) Department of Nuclear Medicine, School of Medicine, Seoul National University, Seoul, Korea
Abstract:
Background
Elucidating the molecular mechanisms by which tumors become resistant to Herceptin is critical for the treatment of Her2-overexpressed metastatic breast cancer.